Faculty of 1000 Biology | Faculty member: Susan Ott

6-Jul-2008

	Susan Ott Department of Medicine, University of Washington, Seattle, United States of America
	Faculty Member: PHARMACOLOGY & DRUG DISCOVERY > Endocrine & metabolic pharmacology [ since 29 August 2006 ]

Home page

http://courses.washington.edu/bonephys

email [Help]

Evaluations

Mechanical stimulation of bone in vivo reduces osteocyte expression of sost/sclerostin.
Robling AG, Niziolek PJ, …, Harris SE, Turner CH
J Biol Chem 2008 Feb 29 283(9):5866-75 [abstract on PubMed] [related articles] [full text] [order article]

Selected by | Susan Ott
Evaluated 12 Mar 2008

A homozygous missense mutation in human KLOTHO causes severe tumoral calcinosis.
Ichikawa S, Imel EA, …, White KE, Econs MJ
J Clin Invest 2007 Sep 117(9):2684-91 [abstract on PubMed] [related articles] [FREE full text]

Selected by | Susan Ott
Evaluated 18 Oct 2007

Selected by | Susan Ott
Evaluated 27 Jul 2007

Rosiglitazone causes bone loss in mice by suppressing osteoblast differentiation and bone formation.
Ali AA, Weinstein RS, …, Manolagas SC, Jilka RL
Endocrinology 2005 Mar 146(3):1226-35 [abstract on PubMed] [related articles] [FREE full text]

Selected by | Susan Ott
Evaluated 20 Feb 2007

Regulation of fibroblast growth factor-23 signaling by klotho.
Kurosu H, Ogawa Y, …, Moe OW, Kuro-o M
J Biol Chem 2006 Mar 10 281(10):6120-3 [abstract on PubMed] [related articles] [FREE full text]

Selected by | Susan Ott
Evaluated 20 Dec 2006

Selected by | Susan Ott
Evaluated 2 Nov 2006

Msx2 promotes cardiovascular calcification by activating paracrine Wnt signals.
Shao JS, Cheng SL, …, Loewy AP, Towler DA
J Clin Invest 2005 May 115(5):1210-20 [abstract on PubMed] [related articles] [FREE full text]

Selected by | Susan Ott
Evaluated 7 Sep 2006